Supportive Care in Cancer

, Volume 14, Issue 10, pp 999–1011 | Cite as

Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review

  • Catherine A. Hauser
  • Martin R. Stockler
  • Martin H. N. Tattersall
Review Article


Goals of work

To review the literature and develop a conceptual framework about prognostic factors for people presenting to medical oncologists with recently diagnosed incurable cancer.

Materials and methods

Medline was searched from January 2000 to October 2003 to identify articles testing associations between clinical or laboratory variables and survival time in adults with advanced solid tumours and median survival of 3 to 24 months. We recorded how frequently prognostic factors were significantly associated with survival in univariable and multivariable analyses.


There were 53 studies included. The factors associated with survival were organised into four categories related to attributes of the host the tumour, the treatment and the interactions between host, tumour and treatment (symptoms, quality of life, performance status and laboratory tests). Co-morbidity was consistently associated with shorter survival. Age and gender were not consistently associated with survival duration, except in lung cancer where females survived longer. Tumour-related factors associated with shorter survival included primary tumour (lung), metastatic site (liver, brain and visceral) and disease extent. Symptoms associated with shorter survival included those of the anorexia–cachexia syndrome, dyspnoea, pain and impaired physical well being. Performance status was strongly associated with survival in most studies. Laboratory tests associated with shorter survival included anaemia, thrombocytopenia, hypoalbuminaemia and elevated serum levels of both alkaline phosphatase and lactate dehydrogenase.


Prognostic factors in patients with advanced cancer can be conceptualised as attributes of the host, tumour, treatment and interactions between the three reflected in symptoms, quality of life performance status and laboratory tests.


Prognosis Prognostic factor Advanced cancer 


  1. 1.
    Christakis NA, Lamont EB (2000) Extent and determinants of error in doctors’ prognoses in terminally ill patients: prospective cohort study. BMJ 320(7233):469–472PubMedCrossRefGoogle Scholar
  2. 2.
    Glare P, Virik K, Jones M et al (2003) A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ 327(7408):195PubMedCrossRefGoogle Scholar
  3. 3.
    Chow E, Harth T, Hruby G et al (2001) How accurate are physicians’ clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. Clin Oncol (R Coll Radiol) 13(3):209–218Google Scholar
  4. 4.
    Vigano A, Dorgan M, Buckingham J et al (2000) Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med 14(5):363–374PubMedCrossRefGoogle Scholar
  5. 5.
    Maltoni M, Amadori D (2002) Prognosis in advanced cancer. Hematol Oncol Clin North Am 16(3):715–729PubMedCrossRefGoogle Scholar
  6. 6.
    Morita T, Tsunoda J, Inoue S, Chihara S (1999) The palliative prognostic index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 7(3):128–133PubMedCrossRefGoogle Scholar
  7. 7.
    Pirovano M, Maltoni M, Nanni O et al (1999) A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian multicenter and study group on palliative care. J Pain Symptom Manage 17(4):231–239PubMedCrossRefGoogle Scholar
  8. 8.
    Glare P, Virik K (2001) Independent prospective validation of the PaP score in terminally ill patients referred to a hospital-based palliative medicine consultation service. J Pain Symptom Manage 22(5):891–898PubMedCrossRefGoogle Scholar
  9. 9.
    Milsted RA, Tattersall MH, Fox RM, Woods RL (1980) Cancer chemotherapy—what have we achieved? Lancet 1(8182):1343–1346PubMedCrossRefGoogle Scholar
  10. 10.
    Tattersall MH, Thomas H (1999) Recent advances: oncology. BMJ 318(7181):445–448PubMedGoogle Scholar
  11. 11.
    Radzikowska E, Glaz P, Roszkowski K (2002) Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20561 cases. Ann Oncol13(7):1087–1093PubMedCrossRefGoogle Scholar
  12. 12.
    Werner-Wasik M, Scott C, Cox JD et al (2000) Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48(5):1475–1482PubMedGoogle Scholar
  13. 13.
    Buccheri G, Torchio P, Ferrigno D (2003) Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 97(12):3044–3052PubMedCrossRefGoogle Scholar
  14. 14.
    Le Chevalier TBD, Soria JC, Douillard JY et al (2001) Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 6(Suppl 1):8–11PubMedCrossRefGoogle Scholar
  15. 15.
    Eton DT, Fairclough DL, Cella D et al (2003) Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 21(8):1536–1543PubMedCrossRefGoogle Scholar
  16. 16.
    Ando M, Ando Y, Hasegawa Y et al (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85(11):1634–1639PubMedCrossRefGoogle Scholar
  17. 17.
    Nakahara Y, Mochizuki Y, Miyamoto Y et al (2002) Mental state as a possible independent prognostic variable for survival in patients with advanced lung carcinoma. Cancer 94(11):3006–3015PubMedCrossRefGoogle Scholar
  18. 18.
    Kodani T, Ueoka H, Kiura K et al (2002) A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer 36(3):313–319PubMedCrossRefGoogle Scholar
  19. 19.
    MacRae R, Shyr Y, Johnson D, Choy H (2002) Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 64(1):37–40PubMedCrossRefGoogle Scholar
  20. 20.
    Firat S, Byhardt RW, Gore E (2002) Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 54(2):357–364PubMedGoogle Scholar
  21. 21.
    Orditura M, De Vita F, Catalano G et al (2002) Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res 22(11):1129–1135PubMedCrossRefGoogle Scholar
  22. 22.
    Orditura M, Romano C, De Vita F et al (2000) Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother 49(10):530–536PubMedCrossRefGoogle Scholar
  23. 23.
    McMillan DC, Elahi MM, Sattar N et al (2001) Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41(1–2):64–69PubMedCrossRefGoogle Scholar
  24. 24.
    Sloan JA, Loprinzi CL, Laurine JA et al (2001) A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol 19(15):3539–3546PubMedGoogle Scholar
  25. 25.
    Chow E, Fung K, Panzarella T et al (2002) A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys 53(5):1291–1302PubMedCrossRefGoogle Scholar
  26. 26.
    Vigano A, Bruera E, Jhangri GS et al (2000) Clinical survival predictors in patients with advanced cancer. Arch Intern Med 160(6):861–868PubMedCrossRefGoogle Scholar
  27. 27.
    Shadbolt B, Barresi J, Craft P (2002) Self-rated health as a predictor of survival among patients with advanced cancer. J Clin Oncol 20(10):2514–2519PubMedCrossRefGoogle Scholar
  28. 28.
    Bachelot T, Ray-Coquard I, Catimel G et al (2000) Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 11(2):151–156PubMedCrossRefGoogle Scholar
  29. 29.
    De Vita F, Orditura M, Galizia G et al (2000) Serum interleukin-10 is an independent prognostic factor in advanced solid tumors. Oncol Rep 7(2):357–361PubMedGoogle Scholar
  30. 30.
    Gamburg ES, Regine WF, Patchell RA et al (2000) The prognostic significance of midline shift at presentation on survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 48(5):1359–1362PubMedGoogle Scholar
  31. 31.
    Kohne CH, Cunningham D, Di CF et al (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13(2):308–317PubMedCrossRefGoogle Scholar
  32. 32.
    Massacesi C, Norman A, Price T et al (2000) A clinical nomogram for predicting long-term survival in advanced colorectal cancer. Eur J Cancer 36(16):2044–2052PubMedCrossRefGoogle Scholar
  33. 33.
    Maisey NR, Norman A, Watson M et al (2002) Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 38(10):1351–1357PubMedCrossRefGoogle Scholar
  34. 34.
    Bensmaine MA, Marty M, de Gramont A et al (2001) Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/−folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br J Cancer 85(4):509–517PubMedCrossRefGoogle Scholar
  35. 35.
    Massacesi C, Pistilli B, Valeri M et al (2002) Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. Am J Clin Oncol 25(2):140–148PubMedCrossRefGoogle Scholar
  36. 36.
    Ruo L, Gougoutas C, Paty PB et al (2003) Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 196(5):722–728PubMedCrossRefGoogle Scholar
  37. 37.
    Yuste AL, Aparicio J, Segura A et al (2003) Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer 2(4):231–234PubMedCrossRefGoogle Scholar
  38. 38.
    Alexandre J, Bleuzen P, Bonneterre J et al (2000) Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 18(3):562–573PubMedGoogle Scholar
  39. 39.
    Luoma ML, Hakamies-Blomqvist L, Sjostrom J et al (2003) Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. Eur J Cancer 39(10):1370–1376PubMedCrossRefGoogle Scholar
  40. 40.
    Kramer JA, Curran D, Piccart M et al (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36(12):1498–1506PubMedCrossRefGoogle Scholar
  41. 41.
    Wyld L, Gutteridge E, Pinder SE et al (2003) Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 89(2):284–290PubMedCrossRefGoogle Scholar
  42. 42.
    Shimozuma K, Sonoo H, Ichihara K, Tanaka K (2000) The prognostic value of quality-of-life scores: preliminary results of an analysis of patients with breast cancer. Surg Today 30(3):255–261PubMedCrossRefGoogle Scholar
  43. 43.
    Engelken FJ, Bettschart V, Rahman MQ et al (2003) Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol 29(4):368–373PubMedCrossRefGoogle Scholar
  44. 44.
    Ridwelski K, Meyer F, Ebert M et al (2001) Prognostic parameters determining survival in pancreatic carcinoma and, in particular, after palliative treatment. Dig Dis 19(1):85–92PubMedCrossRefGoogle Scholar
  45. 45.
    Tas F, Aykan F, Alici S et al (2001) Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 24(6):547–550PubMedCrossRefGoogle Scholar
  46. 46.
    Ueno H, Okada S, Okusaka T, Ikeda M (2000) Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59(4):296–301PubMedCrossRefGoogle Scholar
  47. 47.
    Ikeda M, Okada S, Tokuuye K et al (2001) Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 91(3):490–495PubMedCrossRefGoogle Scholar
  48. 48.
    Roychowdhury DF, Hayden A, Liepa AM (2003) Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol 21(4):673–678PubMedCrossRefGoogle Scholar
  49. 49.
    Sengelov L, Kamby C, von der Maase H (2001) Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol 39(6):634–642PubMedCrossRefGoogle Scholar
  50. 50.
    Stadler WM, Hayden A, von der Maase H et al (2002) Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 7(4):153–157PubMedCrossRefGoogle Scholar
  51. 51.
    Sengelov L, Kamby C, Geertsen P et al (2000) Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Pharmacol 46(5):357–364PubMedCrossRefGoogle Scholar
  52. 52.
    Bellmunt J, Albanell J, Paz-Ares L et al (2002) Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95(4):751–757PubMedCrossRefGoogle Scholar
  53. 53.
    Fujisaki S, Tomita R, Nezu T et al (2001) Prognostic studies on gastric cancer with concomitant liver metastases. Hepatogastroenterology 48(39):892–894PubMedGoogle Scholar
  54. 54.
    Louvet C, Carrat F, Mal F et al (2003) Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer Investig 21(1):14–20CrossRefGoogle Scholar
  55. 55.
    O’Gorman P, McMillan DC, McArdle CS (2000) Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 37(1):36–40PubMedCrossRefGoogle Scholar
  56. 56.
    De Vita F, Romano C, Orditura M et al (2001) Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 21(1):45–52PubMedCrossRefGoogle Scholar
  57. 57.
    Shimada H, Kitabayashi H, Nabeya Y et al (2003) Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 133(1):24–31PubMedCrossRefGoogle Scholar
  58. 58.
    Ogawa K, Toita T, Sueyama H et al (2002) Brain metastases from esophageal carcinoma: natural history, prognostic factors, and outcome. Cancer 94(3):759–764PubMedCrossRefGoogle Scholar
  59. 59.
    Dowling AJ, Czaykowski PM, Krahn MD et al (2000) Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. J Urol 163(5):1481–1485PubMedCrossRefGoogle Scholar
  60. 60.
    Hernes EH, Linja M, Fossa SD et al (2000) Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors. BJU Int 86(3):240–247PubMedCrossRefGoogle Scholar
  61. 61.
    Keilholz U, Martus P, Punt CJ et al (2002) Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 38(11):1501–1511PubMedCrossRefGoogle Scholar
  62. 62.
    Scholz HS, Benedicic C, Haas J et al (2001) Stage IV ovarian cancer: prognostic factors and survival beyond 5 years. Anticancer Res 21(5):3729–3732PubMedGoogle Scholar
  63. 63.
    Ljungberg B, Landberg G, Alamdari FI (2000) Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 34(4):246–251PubMedCrossRefGoogle Scholar
  64. 64.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRefGoogle Scholar
  65. 65.
    Bruera E (1997) ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 315(7117):1219–1222PubMedGoogle Scholar
  66. 66.
    McMillan DC, Watson WS, O’Gorman P et al (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39(2):210–213PubMedCrossRefGoogle Scholar
  67. 67.
    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846–1850PubMedCrossRefGoogle Scholar
  68. 68.
    Yun YH, Heo DS, Heo BY et al (2001) Development of terminal cancer prognostic score as an index in terminally ill cancer patients. Oncol Rep 8(4):795–800PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Catherine A. Hauser
    • 1
  • Martin R. Stockler
    • 1
    • 2
    • 3
  • Martin H. N. Tattersall
    • 1
    • 2
  1. 1.Sydney Cancer CentreRoyal Prince Alfred HospitalCamperdownAustralia
  2. 2.Department of Cancer Medicine, Blackburn Building DO6University of SydneySydneyAustralia
  3. 3.NH&MRC Clinical Trials CentreCamperdownAustralia

Personalised recommendations